Open AccessInfectious Retrovirus Is Inactivated by Serum but Not by Cerebrospinal Fluid or Fluid from Tumor Bed in Patients with Malignant Glioma
Author(s) -
Shimizu Keiji,
Miyao Yasuyoshi,
Tamura Masakazu,
Kishima Haruhiko,
Ohkawa Motohisa,
Mabuchi Eiichiro,
Yamada Masanobu,
Hayakawa Toru,
Ikenaka Kazuhiro
Publication year - 1995
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1995.tb03013.x
Subject(s) - retrovirus , glioma , cerebrospinal fluid , recombinant dna , titer , virology , in vivo , pathology , immunology , biology , virus , medicine , gene , cancer research , biochemistry , microbiology and biotechnology
Intravenous gene transfer using recombinant retroviruses tends to suffer from a low infectious viral titer when conducted in vivo. This is, in part, caused by complement‐mediated proteolytic inactivation of the retrovirus in human serum. However, if the retroviruses were directly injected into the brain, they might not be inactivated. Supernatant from amphotropic retrovirus‐producing cells harboring the BAG vectors was incubated with sera or cerebrospinal fluid (CSF) of patients with gliomas or unrelated disorders. The retroviruses were severely inactivated in sera. However, no such inactivation was noted in CSF or fluid from the tumor bed of glioma patients. These data suggest that gene transfer using recombinant retroviruses could be done into the cavity after removal of the tumor in glioma patients.